Tagged as: Biosimilar User Fee Act

FDA to Hold Final Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act

Tomorrow, March, 22, 2022, the FDA will host a public meeting entitled “Final Assessment of the Program for Enhanced Review Transparency and Communication in in the Biosimilar User Fee Act.”  As part of the Biosimilar User Fee Act (BsUFA), the FDA contracted with independent third parties to assess the extent…

Read More